Cosmo clinches $25m deal with mystery partner for topical candidate
This article was originally published in Scrip
Executive Summary
Italian firm Cosmo Pharmaceuticals has licensed a non-core topical product in early clinical development to an unnamed US firm that it describes as "one of the world's leading specialty pharmaceutical companies". It stands to receive up to $25 million in upfront, milestone and royalty payments based on the development and commercialisation of CB-03-01, an anti-androgen drug that it had earmarked for Phase II studies in acne and androgenic alopecia.